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Abstract
Background: Decentralization of DOTS has increased the number of cured smear-positive
tuberculosis (TB) patients. However, the rate of recurrence has increased mainly due to HIV
infection. Recurrence rate could be taken as an important measure of long-term success of TB
treatment. We aimed to find out the rate of recurrence in smear-positive patients cured under
DOTS in southern Ethiopia.
Methods: We did a retrospective cohort study on cured smear-positive TB patients who were
treated from 1998 to 2006. Recurrence of smear-positive TB was used as an outcome measure.
Person-years of observation (PYO) were calculated per 100 PYO from the date of cure to date of
interview. Kaplan-Meier and Cox-regression methods were used to determine the survival and the
hazard ratio (HR).
Results: 368 cured smear-positive TB patients which were followed for 1463 person-years. Of
these, 187 patients (50.8%) were men, 277 patients (75.5%) were married, 157 (44.2%) were
illiterate, and 152 patients (41.3%) were farmers. 15 of 368 smear-positive patients had recurrence.
The rate of recurrence was 1 per 100 PYO (0.01 per annum). Recurrence was not associated with
age, sex, occupation, marital status and level of education.
Conclusion: High recurrence rate occurred among smear-positive patients cured under DOTS.
Further studies are required to identify factors contributing to high recurrence rates to improve
disease free survival of TB patients after treatment.
Background
The World Health Organization (WHO) recommends
directly observed treatment short-course (DOTS) to con-
trol tuberculosis (TB). It advocates early case detection
and prompt treatment to ensure long-term success by
reducing transmission, recurrence (relapse or reinfection)
and death [1].
Decentralized DOTS implementation has increased the
number of successfully treated TB patients [2-5]. However,
in some countries, the incidence of TB has increased, as
has the risk of defaulting, failure, death and recurrence,
mainly because of the HIV epidemic [6,7]. Therefore,
recurrence and death in successfully treated TB patients
could be taken as an important measure of the efficacy of
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ing TB patients after completing treatment.
Post-treatment studies reported high recurrence rate in TB
patients (36%) after 22 months of follow-up [8]. The
recurrence rates were high among patients infected with
HIV infected and multidrug resistant (MDR) TB (cases
with strains resistant at least to isoniazid and rifampicin)
[8-10]. This may increase TB incidence and reduce the
treatment success [11,12].
In Ethiopia, the success of TB control is affected by the
shortage of health workers to conduct case finding and
treatment supervision [4]. In such settings, poor treatment
adherence and extended treatment regimen could com-
promise the long-term efficacy of TB treatment by increas-
ing the rate of recurrence, transmission of infection and
emergence of drug resistance [13].
To our knowledge, no follow-up study has been con-
ducted in Ethiopia to determine recurrence rates in cured
smear-positive TB patients. The aim of the study was to
find out the rate of recurrence through community based
follow-up of smear-positive TB patients cured under
DOTS.
Methods
Study area and population
We did this study in Dale and Wonsho districts of Sidama
zone in the southern Ethiopia (Figure 1). It is a densely
populated agrarian community (with a population of
296, 811). DOTS was started in 1996 [14] and six health
facilities were providing TB service in the study area.
Trained general health workers administer directly
observed treatment. Standard recording and reporting for-
mats were used in the health facilities and the districts.
District TB programme experts regularly checked the com-
pleteness and accuracy of the recording in the unit TB reg-
ister. The estimated prevalence of TB in the study area was
643 per 105 population; and the incidence of smear-posi-
tive cases was168 per 105 population for 2006 [4]. The
case detection, cure and treatment success rates were 41%,
58% and 76% respectively. The sputum conversion rate at
second month of follow-up was 83% (unpublished report
from the study area).
Study design
This was a retrospective cohort study based on TB patients
that were registered in unit TB registers in the health facil-
ities providing DOTS. We enrolled new and retreatment
cases that were reported cured from 1998 to 2006 through
house-to-house visit.
Map of the study area in Sidama zone in the southern EthiopiaFigure 1
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TB patients who had productive cough for two weeks or
more with at least two positive sputum smears or one pos-
itive smear and x-ray findings consistent with active PTB
were classified as smear-positive pulmonary TB cases.
TB patients received two months intensive phase and six
months continuation phase treatment. Follow-up sputum
examination was done at the end of 2nd, 5th and 7th
months of treatment. A smear-positive TB patient who
had negative sputum smear result in the last month of
treatment and on at least one previous occasion (2nd or 5th
month) was reported as cured. The term recurrence was
used to indicate rediagnosis of smear-positive TB in
patients who were reported cured [8].
Data collection
From unit TB register in health institutions in the two dis-
tricts, we obtained the list of smear-positive TB patients
who were declared cured from 1998 to 2006. We collected
information about unit register number, name, age, sex,
address, TB category, smear result and the treatment out-
come. The data was crosschecked with the district TB reg-
ister that contained the list of the patients treated in the
health institutions in the districts. Trained health exten-
sion workers conducted house-to-house visits, and col-
lected data from the TB patients or their households. They
collected the information if the TB patient were alive, had
symptoms of TB and registered the date of the interview
using structured questionnaire. The data collection was
done from September 2007 to February 2008. HIV results
were not available for TB patients enrolled in our study.
Data analysis
We used SPSS 14 for Windows for data entry and analysis.
We described the patients by age, sex, TB category, marital
status, level of education and occupation. The outcome
measure was recurrence of TB. Person-years of observation
(PYO) were calculated from the date of cure to date of
interview.
We used the Kaplan-Meier method to find out the event-
free survival and the log-rank test for the statistical signif-
icance. Cox-regression method was used to determine the
hazard ratio (HR) and 95% Confidence interval (95%CI).
Recurrence rate was calculated as the number of recur-
rences per 100 PYO. P-value less than 0.05 was considered
significant.
Ethical clearance
The Ethical Review Committee of the Regional Health
Bureau approved this study. After explaining the aim of
the study, we obtained informed consent from the study
participants or head of the household. Patients with
recent history of cough and other symptoms suggestive of
TB were advised to visit health posts for sputum collection
by health extension workers or to visit diagnostic health
institutions for examination.
Results
Of the 397 smear-positive TB patients registered, 368
(92.7%) were followed. Incomplete information was
obtained for 29 (7.3%) of which 8(2.0%) had moved to
other districts. However, no difference was observed by
age, sex, and TB category compared o the patients we
enrolled.
Of the 368 smear-positive TB patients which were fol-
lowed, 187 patients (50.8%) were men, 277 patients
(75.5%) were married, 157 (44.2%) were illiterate, and
152 patients (41.3%) were farmers (Table 1). 368 cured
smear-positive TB patients were followed for 1463 per-
son-years. 15 of 368 smear-positive patients had recur-
rence. The mean (median) duration of follow-up was 3.87
(4.0) years. The rate of recurrence was 1 per 100 PYO
(0.01 per annum). Recurrence was not associated with
age, sex, occupation, marital status and level of education
(Table 2).
Discussion
The estimated recurrence rate in our study area was 1 per
100 PYO. This could be explained by HIV infection, MDR
TB, reinfection due to high TB burden and inadequate
treatment supervision and patient follow-up.
HIV infection increases the risk of infection, reinfection,
recurrence and death. It also increased the workload by
fuelling TB epidemic and affected the performance of TB
programme [6]. In southern Ethiopia, the prevalence of
HIV infection in the general population and TB patients
was 3.8% and 17.5% respectively [15]. This could be one
of the factors to explain the high recurrence rate in our set-
ting. However, the role of HIV in recurrence requires fur-
ther investigation.
Higher recurrence rates reported elsewhere, 8.6% in Viet-
nam after 19 months, 11% in India after two and half
years and 36% in Kazakhstan after 22 months of follow-
up [16-18] were attributed to MDR TB, poor treatment
supervision and inadequate patient follow-up
[8,9,11,12]. Though the prevalence of MDR TB in Ethio-
pia was believed to be low (1.6% in new and 12% in pre-
viously treated TB cases), 50% resistance to one or more
drugs in re-treatment cases was reported) [19]. Similarly
7.7% resistance to at least one TB drug was reported from
our study area [20]. This may also be one of the factors to
explain the high recurrence rate in our setting.
Moreover, factors that affect the performance of TB pro-
gramme (poor treatment supervision and failure to do fol-Page 3 of 5
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condition could increase the recurrence rate. Inadequate
treatment supervision, more pronounced during continu-
ation phase when patients receive unsupervised treat-
ment, reduces treatment adherence and increases the risk
of treatment failure and MDR TB. This is worsened when
the importance of treatment adherence is not well
addressed during health education sessions [21]. Addi-
tionally, failure to conduct follow-up sputum examina-
tion reduces the chance of detecting failure cases (smear-
positive at 5th or 7th month) without affecting the number
of patients that complete treatment under DOTS. Thus, in
routine practice where cure is based on smear microscopy,
treatment failure can be missed.
The limitation of the study were using sputum microscopy
for the diagnosis of recurrence in smear-positive patients
that may have underestimated the rates of recurrence and
lack of HIV test result to estimate the role of HIV in recur-
rence.
The significance of this study is more in settings with high
TB and HIV prevalence. In such settings high disease trans-
mission may maintain the burden of TB in the commu-
nity. Yet, high recurrence rates in cured smear-positive TB
patients should alert TB programme managers to identify
the risk factors. The performance of TB programme could
be improved by addressing factors that affect treatment
adherence and increase the risk of MDR TB. TB patients
could also benefit from the access to HIV prevention and
control measures in high-risk patients to reduce recur-
rence and improve their long-term survival.
Conclusion
The rate of recurrence in cured smear-positive TB patients
was high in our setting. Further studies are required to
identify risk factors for recurrence to improve the disease
free survival of cured smear-positive TB patients.
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Table 1: Socio-demographic characteristics of cured smear-
positive patients in southern Ethiopia from 1998 - 2006
Variables number Percent (%)
Sex
Male 187 50.8%
Female 181 49.2%
Marital status
Single 90 24.5%
Married 268 73.0%
Divorced/widowed 9 2.5%
Missing 1
Level of education
Illiterate 157 44.2%
1 - 4 57 16.1%
5 - 8 120 33.8%
9 + 21 5.9%
Missing 13
Occupation
Student 64 17.4%
Farmer 152 41.3%
Housewife 35 9.5%
Merchant 16 4.3%
Others 101 27.4%
Current status
New 364 98.9%
Retreatment 4 1.1%
Table 2: Factors predicting recurrence in cured smear-positive tuberculosis patients in southern Ethiopia from 1998 - 2006
Variables Recurrence PYO* Recurrence rate per 100PYO Crude HR (95%CI)† P - value
Yes No
Age (in years)
< 15 0 28 122 0.0 1.0
≥15 14 324 1330 1.1 0.0 (0.0 - 170) 0.5
Sex
Female 5 176 710 7.0 1.0
Male 10 177 753 1.3 1.8 (0.6 - 5.5) 0.3
Level of education
Illiterate 5 152 629 0.8 1.0
Literate 9 189 783 1.2 0.7 (0.2 - 1.9) 0.5
Marital status
Never married 1 89 338 0.3 1.0
Married 14 263 1118 1.3 03 (0.03 - 1.9) 0.2
Occupation
Farmers 12 239 997 1.2 1.0
Non farmers 3 114 466 0.6 1.9 (0.5 - 6.6) 0.3
* PYO - person-year observation
† HR - hazard ratio, 95%CI - 95% confidence intervalPage 4 of 5
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